Li Yongzhong, Li Bin, Chen Li, Dong Junxing, Xia Ziming, Tian Ying
Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
J Inorg Biochem. 2023 Jan;238:112034. doi: 10.1016/j.jinorgbio.2022.112034. Epub 2022 Oct 21.
During the wide utilization of the actinides in medicine, energy, military, and other fields, internal contaminations can profoundly endanger human health and public security. Chelating decorporation agents are the most effective therapies to reduce internal contamination that includes radiological and chemical toxicities. This review introduces the structures of chelating decorporation agents including inorganic salts, polyaminocarboxylic acids, peptides, polyphosphonates, siderophores, calixarenes, polyethylenimines, and fullerenes, and highlights ongoing advances in their designs and mechanisms. However, there are still numerous challenges that block their applications including coordination properties, pharmacokinetic properties, oral bioavailability, limited timing of administration, and toxicity. Therefore, additional efforts are needed to push novel decorporation agents with high efficiency and low toxicity for the treatment of internal contamination by actinides.
在锕系元素在医学、能源、军事及其他领域广泛应用的过程中,体内污染会严重危害人类健康和公共安全。螯合促排剂是减少包括放射性和化学毒性在内的体内污染的最有效疗法。本文综述介绍了螯合促排剂的结构,包括无机盐、多氨基羧酸、肽、多膦酸盐、铁载体、杯芳烃、聚乙烯亚胺和富勒烯,并重点介绍了它们在设计和作用机制方面的最新进展。然而,仍有许多挑战阻碍着它们的应用,包括配位性质、药代动力学性质、口服生物利用度、给药时间有限以及毒性等。因此,需要付出更多努力来推动开发高效低毒的新型促排剂,用于治疗锕系元素引起的体内污染。